Exacerbation of Previously Undiagnosed Bird Fancier’s Lung by Pembrolizumab Therapy  Ann Vu, MD, Robert Vassallo, MD, Jay H. Ryu, MD  CHEST  Volume 155, Issue 4, Pages e79-e82 (April 2019) DOI: 10.1016/j.chest.2018.12.002 Copyright © 2018 American College of Chest Physicians Terms and Conditions

Figure 1 A, Chest CT angiography 5½ weeks following initiation of pembrolizumab therapy demonstrating bilateral ground-glass and reticular opacities with an underlying mosaic attenuation pattern. B, CT imaging obtained 4 weeks before the start of pembrolizumab therapy demonstrating preexisting mild ground-glass and reticular opacities bilaterally with an underlying mosaic attenuation pattern. CHEST 2019 155, e79-e82DOI: (10.1016/j.chest.2018.12.002) Copyright © 2018 American College of Chest Physicians Terms and Conditions

Figure 2 A, Chest radiographic imaging prior to the start of steroid therapy for Bird fancier’s lung exacerbated by pembrolizumab therapy. B, Follow-up chest radiographic imaging at 3 months after the diagnosis of Bird fancier’s lung. CHEST 2019 155, e79-e82DOI: (10.1016/j.chest.2018.12.002) Copyright © 2018 American College of Chest Physicians Terms and Conditions